TY  - JOUR
AU  - Wankhede, Durgesh
AU  - Bontoux, Christophe
AU  - Grover, Sandeep
AU  - Hofman, Paul
TI  - Prognostic Role of KRAS G12C Mutation in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
JO  - Diagnostics
VL  - 13
IS  - 19
SN  - 2075-4418
CY  - Basel
PB  - MDPI
M1  - DKFZ-2023-02074
SP  - 3043
PY  - 2023
N1  - #EA:C070#
AB  - KRAS G12C mutation (mKRAS G12C) is the most frequent KRAS point mutation in non-small cell lung cancer (NSCLC) and has been proven to be a predictive biomarker for direct KRAS G12C inhibitors in advanced solid cancers. We sought to determine the prognostic significance of mKRAS G12C in patients with NSCLC using the meta-analytic approach. A protocol is registered at the International Prospective Register for systematic reviews (CRD42022345868). PubMed, EMBASE, The Cochrane Library, and Clinicaltrials.gov.in were searched for prospective or retrospective studies reporting survival data for tumors with mKRAS G12C compared with either other KRAS mutations or wild-type KRAS (KRAS-WT). The hazard ratios (HRs) for overall survival (OS) or Disease-free survival (DFS) of tumors were pooled according to fixed or random-effects models. Sixteen studies enrolling 10,153 participants were included in the final analysis. mKRAS G12C tumors had poor OS [HR, 1.42; 95
KW  - KRAS (Other)
KW  - KRAS G12C (Other)
KW  - NSCLC (Other)
KW  - meta-analysis (Other)
KW  - non-small cell lung cancer (Other)
KW  - systematic review (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37835787
C2  - pmc:PMC10572143
DO  - DOI:10.3390/diagnostics13193043
UR  - https://inrepo02.dkfz.de/record/284763
ER  -